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Abstract 
Poly(ADP-ribose)polymerase-1 (PARP-1) is an important target for drug design for several 
therapeutic applications. 5-Aminoisoquinolin-1-one (5-AIQ) is a highly water-soluble lead 
compound; synthetic routes to 3-substituted analogues were explored. Tandem Hurtley 
coupling of -diketones with 2-bromo-3-nitrobenzoic acid, retro-Claisen acyl cleavage and 
cyclisation gave the corresponding 3-substituted 5-nitroisocoumarins. Treatment with 
ammonia at high temperature and reduction with tin(II) chloride gave eleven target 3-
substituted 5-AIQs, which were all soluble in water (>1% w/v) as their HCl salts. Most were 
more potent than 5-AIQ as inhibitors of PARP-1 and of PARP-2 in vitro, the most active 
being 5-amino-3-methylisoquinolin-1-one (PARP-1: IC50 = 0.23 M vs. IC50 = 1.6 M for 5-
AIQ). Some rationalisation of the SAR was achieved through molecular modelling. 
1. Introduction 
The poly(ADP-ribose)polymerases (PARPs) comprise a superfamily of enzymes which use 
NAD
+
 to generate electrophilic ADP-ribose units to attach to substrate proteins to build poly-
anionic poly(ADP-ribose) polymers.
1
 Two of the isoform members of this superfamily, the 
archetypal PARP-1 and PARP-2, detect sites of damage in DNA and use this poly(ADP-
ribosyl)ation to open the chromatin structure and initiate and regulate repair of DNA.
1-3
 Other 
members of the superfamily (e.g. PARP-3, PARP-4 (vault mPARP) and PARPs-5a,b (the 
tankyrases) have other regulatory functions within the cell.
1-6
 Inhibitors of PARP-1 are in 
clinical trial for the treatment of cancer
7-9
 and have demonstrated beneficial activity in 
experimental models in a range of other therapeutic applications, including inflammation,
10,11
 
organ damage following ischaemia-reperfusion,
12,13
 neurological damage,
14,15
 organ trans-
plant
16
 and multiple sclerosis.
17 
The known pharmacophore for optimum inhibition of PARP-1 comprises a lactam fused to an 
aromatic ring (e.g. quinazolin-4-one, isoquinolin-1-one or phthalazin-1-one) or a similar 
primary benzamide where the conformation of the C=O—NH is held in the plane of the 
benzene ring by an intramolecular hydrogen bond. This benzamide amide motif is required 
for hydrogen bonding to the conserved Gly
863
 and Ser
904
 and -stacking with Tyr907 in the 
(NAD
+
)-nicotinamide-binding site. The clinical candidates olaparib 1, veliparib 2 and 
rucaparib 3 (Figure 1) fit this model. 5-Aminoisoquinolin-1-one (5-AIQ, 4, Figure 1) is an 
inhibitor of PARP-1 and PARP-2, which is highly water-soluble as its hydrochloride salt. 
Interestingly, 4 shows potent therapeutic activity in models in vivo of a range of diseases and 
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disorders, including haemorrhagic shock,
18
 
myocardial infarction,
12
 colitis
19
 and cerebral 
ischaemia.
15
 In the context of cancer, it inhibits 
angiogenesis
20
 (PARP-1 regulates NF-B) and 
is potently antimetastatic,
21
 inter alia. 
Exploring the structure-activity relationships 
around this core, we have reported that 4-aryl-
5-AIQs and 5-benzamidoisoquinolin-1-ones 
are isoform-selective inhibitors of PARP-2.
22,23
 
6-Arylthieno[3,4-c]pyridin-4(5H)ones inhibit 
PARP-1,
24
 so we proposed that the analogous 
3-substituted-5-AIQs should be explored.  
We have previously reported the synthesis of 4 
by condensation of methyl 2-methyl-3-nitro-
benzoate with dimethylformamide dimethyl 
acetal (DMFDMA) to give 5-nitroisocoumarin, 
followed by conversion to 5-nitroisoquinolin-
1-one with ammonia and reduction of the nitro 
group.
18
 However, this method could not be 
extended to the 3-methyl analogue
25
 and 
extension to the 3-aryl analogues was 
precluded by difficulty in accessing the 
required benzamide acetals. 3-Aryl-5-nitroiso-
coumarins 5 have been accessed by Castro-
Stevens coupling of 2-iodo-3-nitrobenzoic acid 
6 with arylethynes, followed by cyclisation in 
situ (Scheme 1) but this process was limited to 
three examples.
26
 Sonogashira coupling of 
methyl 2-iodo-3-methylbenzoate 7 with 
phenylethynes was investigated, followed by 
cyclisation with Hg
2+
 as catalyst but this was 
only effective for one example (R
3
 = Ph).
26
 A 
more general but low-yielding method 
involved Friedel-Crafts acylation of 5-nitroiso-
coumarin 9 with aroyl chlorides under forcing 
conditions in nitrobenzene, followed by in situ 
rearrangement and decarboxylation; this was limited to benzoyl chloride and aroyl chlorides 
carrying electron-withdrawing para-substituents.
27
 There is therefore a need for a more 
general route to 3-substituted-5-nitroisocoumarins and, hence, to 3-substituted analogues of 4. 
In 1929, Hurtley reported the displacement of the halogen from 2-bromobenzoic acid with the 
enolates of -diketones and of -ketoesters in the presence of copper catalysts to form the 
corresponding arylated -dicarbonyl compound.28 He noted “The presence of copper-bronze 
or copper acetate is necessary; the latter appears to be the more vigorous catalyst, but the 
former gives purer products and was used where possible.” Later mechanistic studies have not 
proved fully conclusive.
29
 Most have determined that the carboxylate of the aryl component is 
essential and that bromine is the optimum halogen.
29,30
 Ames and Ribeiro extended this 
process by forcing a retro-Claisen condensation and ring closure on the Hurtley products with 
sodium chloride at 170C to give isocoumarins in moderate yields, making the 3-substituted 
Figure 1. Structures of three inhibitors of PARP-1 in 
advanced clinical trial and of 5-AIQ. 
Scheme 1. Earlier syntheses of 3-substituted-5-
nitroisocoumarins 5. Reagents: i, CuC≡CR3, 
pyridine, reflux (R
3
 = Ph, 4-MePh, 4-MeOPh); ii, 
HC≡CPh, CuI, (Ph3P)2PdCl2, Pr
i
2NH, THF; iii, 
HgSO4, H2SO4, acetone, reflux; iv, R
3
COCl, 
SnCl4, PhNO2. 130C (R
3
 = Ph, Ph-(EWG)). 
isocoumarins available in two steps from 2-bromobenzoic acid and pentane-2,4-dione or 1,3-
diphenylpropane-1,3-dione.
31
 Very recently, Cai et al. developed a one-pot synthesis of 3-
substituted isocoumarins by reaction of 2-iodo- or 2-bromobenzoic acid with -diketones, 
catalysed by copper(I) iodide and potassium phosphate in dimethylformamide under forcing 
conditions in a sealed tube.
32
 No 5-substituted analogues were reported. This tandem process 
has been extended to use of 2-iodobenzanilides, in place of 2-bromobenzoic acid, but Kavala 
et al. note that isocoumarins carrying nitro groups are unstable to the reaction conditions.
33
 
We therefore sought to expand the tandem Hurtley – retro-Claisen – cyclisation reaction to 
the one-pot synthesis of 5-nitro-3-substituted isocoumarins without recourse to sealed tubes. 
2. Results & Discussion 
2-Bromo-3-nitrobenzoic acid 10 (Scheme 2) was 
prepared by mercury-catalysed decarboxylation of 3-
nitrobenzene-1,2-dioic acid (3-nitrophthalic acid), 
followed by treatment of the intermediate aryl-mercury 
with bromine,
34
 by analogy with our previous method for 
2-iodo-3-nitrobenzoic acid.
26
 Many of the -dicarbonyl 
components were commercially available but Claisen 
condensations, either base-catalysed (sodamide) or 
Lewis-acid catalysed (boron trifluoride.acetic acid 
complex), were used to supply others.  
As a preliminary study to establish suitable reaction 
conditions for the reaction, 10 was treated with the tri-
fluoromethylphenyl -diketone 11a, using Hurtley’s 
original reaction conditions (copper powder, with sodium 
ethoxide as base in boiling ethanol)
28
 (Scheme 2). The 
isocoumarin 12a was isolated in modest yield, through a 
tandem Hurtley – retro-Claisen – cyclisation sequence. 
The mono-ketone 13 and the ester 14 were also obtained 
as by-products. Interestingly, there was no evidence for 
formation of 3-methyl-5-nitroisocoumarin, arising from 
an alternative retro-Claisen reaction in the sequence, nor 
were the intermediate arylated diketone 15 and the 
Scheme 2. Initial investigation of tandem Hurtley – retro-Claisen – cyclisation reaction of 10 with 11 under 
Hurtley’s conditions. Reagents & conditions: i, Cu powder, NaOEt, EtOH, reflux. 
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Scheme 3. Tandem Hurtley – retro-
Claisen – cyclisation reactions of 10 
with methyl -diketones 11a-h to form 
3-substituted 5-nitroisocoumarins 12a-
h. Reagents & conditions: i, Cu powder, 
KOBu
t
, Bu
t
OH, reflux. 
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a: R3 = 4-F3CPh; b: R
3 = Ph; 
c: R3 = 4-MePh; d: R3 = 4-MeOPh; 
e: R3 = 4-ClPh; f: R3 = thiophen-2-
yl; g: R3 = Me; h: R3 = pentyl
intermediate retro-Claisen product 16 observed in the product mixture. Compounds 13 and 14 
are products of retro-Claisen cleavage of the starting -diketone 11a. This suggests that the 
base, ethoxide, may be too nucleophilic, in that it attacks the carbonyls of 11a before the 
Hurtley coupling can take place, consuming 11a and thereby lowering the yield of 12a. 
Replacement of the base with the less nucleophilic potassium t-butoxide and the solvent with 
t-butanol obviated the premature retro-Claisen cleavage (Scheme 3), providing mixtures of 
the required 3-substituted 5-nitroisocoumarin 12a-h and the 3-methyl analogue 12g, arising 
from an alternative retro-Claisen cleavage as the second step. These were readily separated by 
column chromatography. As shown in Table 1, the yields of 12a-h were poor-to-modest. 
Rationalising that material was being lost through the alternative retro-Claisen cleavage of the 
R
3
CO group, we examined the tandem Hurtley – retro-Claisen – cyclisation reaction sequence 
with symmetrical -diketones 17b,d,h-k (Scheme 4). As for the unsymmetrical analogues 11, 
Isocoumarin 3-
substituent 
Reaction of 10 with unsymmetrical 
diketones 11 (KOBu
t
 / Bu
t
OH) 
Reaction of 10 with 
symmetrical diketones 
17 (KOBu
t
 / Bu
t
OH) 
Yield of target 
isocoumarin (%) 
Yield of 12g (%) Yield of target 
isocoumarin (%) 
4-F3CPh 16 (12a) 6 ND 
Ph  4 (12b) 8 78 (12b) 
4-MePh 21 (12c) 3 ND 
4-MeOPh 15 (12d) 6 60 (12d) 
4-ClPh 33 (12e) 4 ND 
Thiophen-2-yl 21 (12f) 0 ND 
Me - - 23 (12g) 
pentyl  4 (12h) 0 26 (12h) 
Bn ND ND 32 (12i) 
Et ND ND 24 (12j) 
CH2CHMe2 ND ND 26 (12k) 
 
Table 1. Yields of 5-nitroisocoumarins 12 formed in the tandem Hurtley coupling  retro-
Claisen  cyclisation reactions from 10 and unsymmetrical (11) and symmetrical (17) 
-diketones. ND = not determined. 
Scheme 4. Tandem Hurtley – retro-Claisen – cyclisation reactions of 10 with symmetrical -diketones 11g, 
17b,d,h-k to form 3-substituted 5-nitroisocoumarins 12b,d,g-k and syn thesis of symmetrical -diketone 17i. 
Reagents & conditions: i, Cu powder, KOBu
t
, Bu
t
OH, reflux; ii, NaNH2, Et2O, reflux. 
these were either commercially available 
(17b) or prepared by Claisen condensations. 
Interestingly, during the assembly of the 
dibenzyl symmetrical -diketone 17i from 
ketone 18 and ester 19, a quantity of the 
homo-Claisen product 20 was also formed, 
reflecting the acidity of the -protons in the 
intended electrophilic component 19 
(Scheme 4). The yields of the required 3-
alkyl and 3-aryl 5-nitroisocoumarins 12 were 
markedly higher when the symmetrical 
diketones were employed (Table 1), using the 
same reaction conditions (potassium t-
butoxide in t-butanol). In cases where both 
methods were examined for the same target 12a,d,h, the yield for the tandem reaction with 
the symmetrical diketones 17 was much higher. Indeed, the yields exceeded the sums of the 
yields of (desired isocoumarins + 12g), suggesting that not only was the problem of the wrong 
acyl group being lost in the retro-Claisen step being resolved but also that the initial Hurtley 
reaction was proceeding better with the enolates of 17. The dialkyl symmetrical -diketones 
17g-k gave lower yields than the diaryl analogues 17b,d. 
Thus the tandem reaction provided sufficient quantities of the isocoumarins 17a-k for the 
remainder of the reaction sequence. Notably, the sequence proceeds with alkyl -diketones 
and with aryl groups carrying electron-neutral, +M and –I para-substituents but it fails 
completely with –M substituents on the aryl group, such as nitro and cyano. 
The 5-nitroisocoumarins 12 were readily converted into the corresponding 5-nitroisoquinolin-
1-ones 21 by reaction with ammonia in boiling 2-methoxyethanol (Scheme 5), obviating the 
use of sealed tubes for the more usual transformation in ethanol. The yields were mostly 
good-to-high. Reduction of the nitro group to furnish the target 3-substituted 5-
aminoisoquinolin-1-ones 22 was effected with tin(II) chloride. For one example, 21a, 
catalytic hydrogenation was also explored but gave practical problems of separating the 
product 22a efficiently from the catalyst. 
3. Biochemical evaluation 
All the hydrochloride salts of 5-aminoisoquinolin-1-ones 22a-k showed good water-solubility 
(>1% w/v; > 30 mM). Each was evaluated in vitro for activity against human PARP-1 isolated 
from HeLa nuclear extract, using the KuDOS FlashPlate scintillation proximity assay 
method.
35
 This isotopic assay measures PARP-1 activity through synthesis of [
3
H]-ADP-
ribose polymers from [
3
H]-NAD
+
. Tritium bound to the FlashPlate was counted using a 
scintillation plate reader. In this study, five different concentrations of the inhibitor, in a range 
surrounding the predicted IC50 value, were used. Three independent determinations were per-
formed for each candidate inhibitor 22a-k; the mean IC50 values are reported in Table 2.  
In this assay, the mean IC50 value for PARP-1 inhibition by the lead compound, 5-AIQ 4, was 
found to be 1.6 M, which is higher than that reported previously by us36 for an assay in a 
broken nuclear preparation (300 nM) and that reported by Suto et al.
37
 (250 nM) from a calf-
thymus preparation assay. Differences in absolute values of IC50 between assay types are well 
known for PARP-1 inhibition. All the 3-substituted 5-aminoisoquinolinones inhibited PARP-
Scheme 5. Conversion of the 5-nitroisocoumarins 
12a-k into 5-aminoisoquinolin-1-ones 22a-k. 
Reagents: i, NH3, MeO(CH2)2OH, reflux; ii, SnCl2, 
EtOH or H2, Pc/C, EtOH, aq. HCl. 
1 activity, with many having IC50 
values in the 0.2-1.0 M range. 
Indeed, all except 22f,i were more 
potent than the lead compound 4. 
Generally, the simpler 3-alkyl 
compounds 22g,h,j were slightly 
more potent than the 3-phenyl 
compound 22b; this is in line with 
similar effects noted by White et 
al.
38
 that 8-methoxy-2-
methylquinazolin-4-one is ca. 5-
fold more potent than is 8-meth-
oxy-2-phenylquinazolin-4-one. 
Introduction of branching in the 3-
alkyl chain, in the isobutyl 
analogue 22k and the benzyl 
analogue 12i, however, caused 
some loss of activity. A phenyl 
substituent is accepted at the 3-
position (in 22b), showing that 
steric bulk is unlikely to be the 
simple explanation of the weaker activity of 22i,k. Curiously, the introduction of a thiophene 
ring at the 3-position resulted in a loss of potency in 22f, despite the usually accepted 
pharmacoequivalence of benzene and thiophene.  
Selected compounds were also assayed for their inhibition of PARP-2 activity (Table 2), 
using the assay previously reported by us.
23
 Most of the analogues tested showed slightly 
greater potency against PARP-2 but the selectivity was not large enough to allow use in 
biochemical studies as selective inhibitors. 
4. Molecular modelling studies 
The structures of the 3-substituted 5-AIQs 22a-k were overlaid with the structure of the 
known inhibitor 8-hydroxy-2-methylquinazolin-4-one bound into the NAD
+
-binding site of 
the catalytic domain of chicken PARP-1 derived from co-crystal X-ray data retrieved from the 
Brookhaven Protein Data Bank (PDB code: 4PAX), using Tripos Associates SYBYL 
software on a SGI Octane II workstation. The 3-substituted 5-AIQ derivatives were initially 
positioned such that the central rings were overlaid with the 8-hydroxy-2-methylquinazolin-4-
one rings; the side chains were then subjected to molecular mechanics and molecular 
dynamics calculations while restraining the binding pocket and the heterocyclic core; the 
temperature was ramped to 300 K over 10 ps, then held at 300 K for a further 20 ps. Once an 
optimal orientation had been established for the side-chains, the restraints were removed and 
the whole binding pocket (10 Å) was subjected to further molecular dynamics (20 ps at 300K) 
and then refined with mechanics calculations, allowing free movement of both the ligands and 
the binding pocket. Examples of illustrations generated by these calculations are shown in 
Figure 2. As expected, each isoquinolin-1-one could make hydrogen bonds from the carbonyl 
oxygen to the side-chain O—H of Ser904 and to the backbone N—H of Gly863. For example, in 
the minimised position for the most potent compound, 22g, this oxygen was located 2.25 Å 
from the latter and 1.59 Å from the former (Figure 2A). The isoquinolin-1-one N—H was 
also located appropriately for a strong hydrogen bond to the backbone carbonyl of Gly
863
, as 
exemplified for 22g in Figure 2A with a distance of 2.08 Å. These hydrogen-bonding 
Table 2. IC50 values for inhibition of human PARP-1 
and murine PARP-2 by 3-substituted 5-aminoiso-
quinolin-1-ones. ND = not determined. 
Cpd. 
No. 
3-Substituent PARP-1 
IC50 (M) 
PARP-2 
IC50 (M) 
4 H 1.6  0.25 1.05  0.15 
22a 4-F3CPh 0.33  0.07 0.17  0.02 
22b Ph 1.07  0.07 0.48  0.15 
22c 4-MePh 0.88  0.14 0.12  0.03 
22d 4-MeOPh 0.90  0.45 0.73  0.25 
22e 4-ClPh 0.57  0.03 0.16  0.05 
22f thiophen-2-yl 5.61  2.20 ND 
22g Me 0.23  0.02 0.26  0.05 
22h pentyl 0.32  0.17 ND 
22i Bn 5.14  1.60 ND 
22j Et 0.49  0.04 0.83  0.10 
22k CH2CHMe2 1.17  0.56 ND 
 
interactions are common in the modelled and co-crystal structures of inhibitors. It was also 
observed that the 5-NH2 in these inhibitors was well accommodated within a small binding 
pocket and was orientated and located appropriately for a water-mediated hydrogen bond to 
the carboxylate of the important catalytic Glu
988
 in the active site; an ordered water molecule 
is located in this position in several crystal structures. The core aromatic isoquinolin-1-one 
rings of 22a-k also formed a -stack with the electron-rich aromatic side-chain of Tyr907, as is 
common for PARP-1 inhibitors (illustrated for 22g in Figure 2B). Notably, the bulk of the 
sulfur in 22f (Figure 2C) may possibly interfere with the critical hydrogen bond from the 
inhibitor N—H to Gly863 of the enzyme, diminishing its potency. 
These modelling studies indicated that the 3-substituents of 22a-k should occupy a 
hydrophobic pocket. Figure 2D shows the 3-methyl of 22g entering shallowly into this space, 
whereas the 3-(4-trifluoromethylphenyl) of 22a appears to fill the pocket (Figure 2E), 
reflecting the increased inhibitory potency of these and closely related compounds when 
compared with 4. 
5. Conclusion 
This paper reports a one-pot tandem Hurtley – retro-Claisen – cyclisation reaction sequence, 
which is useful in preparing 3-aryl and 3-alkyl 5-nitroisocoumarins 12. These are important 
intermediates in accessing the corresponding 3-aryl and 3-alkyl 5-aminoisoquinolin-1-ones 
22. The tandem sequence can be carried out with either unsymmetrical or symmetrical -
diketones. The whole preparation of the targets 22 is achieved without recourse to sealed 
tubes, particularly for the Hurtley step and for the isocoumarin-to-isoquinolinone step, which 
have previously required such specialised equipment.
32,39
 This new sequence tolerates most 
Figure 2. Illustrations of modes of binding of selected examples in the NAD
+
-binding site of chicken PARP-1, 
as predicted by molecular modelling. A: Binding of 22g, showing hydrogen bonds to Gly
863
 and Ser
904
 (green 
solid lines) and the proximity of the 5-amine to the carboxylate of Glu
988
(green dotted line). B: Binding of 22g, 
showing -stacking to Tyr907. C: Binding of 22f, showing hydrogen bonds to Gly863 and Ser904 and potential 
steric obstruction by the sulfur. D: View of binding of 22g, showing insertion of the 3-Me into a pocket. E: View 
of binding of 22a, showing insertion of the 3-(4-trifluoromethylphenyl) into a pocket.  
Tyr907
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863B
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groups, except –M substituents on the aryl units in diaryl--diketones. It is therefore 
complementary to our one-pot formation of 3-aryl-5-nitroisocoumarins by Friedel-Crafts 
acylation of 5-nitroisocoumarin, rearrangement and decarboxylation, for which –M 
substituents are optimal.
27 
Many of the 3-substituted 5-AIQ derivatives 22a-k showed moderately more potent inhibition 
of the enzymatic activities of PARP-1 and PARP-2 than the parent 4, although there was no 
selectivity evident for either isoform. As demonstrated by molecular modelling, the 3-
substituents entered a modestly-sized hydrophobic pocket in both enzymes. The ready access 
to these structures through the tandem Hurtley – retro-Claisen – cyclisation reaction sequence 
now enables further structure-activity studies for design and discovery of new inhibitors of 
these clinically important enzymes. 
6. Experimental 
6.1. Chemistry 
Mps were determined using a Reichert-Jung Thermo Galen Kofler block and are uncorrected. 
IR spectra were recorded on a Perkin-Elmer RXI FT-IR spectrometer as KBr discs. NMR 
spectra were recorded on either a JEOL GX 270 (270.05 MHz 
1
H; 67.8 MHz 
13
C) or a JEOL 
EX 400 (399.65 MHz 
1
H; 100.4 MHz 
13
C; 376.05 MHz 
19
F) spectrometer. Mass spectra were 
obtained using a VG 7070 mass spectrometer. Column chromatography was performed using 
silica gel 60 (0.040-0.063 mm, Merck). Experiments were conducted at ambient temperature, 
unless otherwise stated. Solutions in organic solvents were dried using anhydrous MgSO4 and 
solvents were evaporated under reduced pressure. 
6.1.1. 5-Nitro-3-(4-trifluoromethylphenyl)isocoumarin (12a). Method A. 
Compound 10
34
 (2.5 g, 10 mmol) and Cu powder (220 mg, 3.5 mmol) were added to 11a
40
 
(3.5 g, 15 mol) and NaOEt (1.6 g, 23 mmol) in EtOH (35 mL). The mixture was boiled under 
reflux for 16 h, then poured into H2O and acidified with aq. HCl (2 M). Extraction (Et2O), 
evaporation and chromatography (hexane / EtOAc 4:1) gave 12a (160 mg, 5%) as yellow 
crystals, with data as below. Further elution gave 13 (210 mg, 11%) as a colourless oil (lit.
41 
oil): 
1
H NMR (CDCl3)  2.56 (3 H, s, Me), 7.55 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 8.14 (2 H, d, 
J = 8.2 Hz, Ph 2,6-H2). Further elution gave 14 (130 mg, 6%) as a colourless oil (lit.
42 
oil): 
1
H 
NMR (CDCl3)  1.41 (3 H, t, J = 7.2 Hz, Me), 4.41 (2 H, q, J = 7.2 Hz, CH2), 7.75 (2 H, d, J 
= 8.2 Hz, 3,5-H2), 8.16 (2 H, d, J = 8.2 Hz, 2,6-H2). 
6.1.2. 5-Nitro-3-(4-trifluoromethylphenyl)isocoumarin (12a) and 3-methyl-5-nitro-
isocoumarin (12g). Method B. 
Compound 10
34
 (3.6 g, 16 mmol) was boiled under reflux with 11a (760 mg, 3.1 mmol), 
KOBu
t
 (700 mg, 6.3 mmol) and Cu powder (20 mg, 0.3 mmol) in Bu
t
OH (50 mL) for 16 h. 
The mixture was poured into H2O (350 mL) and was acidified with aq. HCl (2 M). Extraction 
(Et2O), evaporation and chromatography (hexane / EtOAc 9:1) gave 12a (160 mg, 16%) as 
yellow crystals: mp 163-164C (lit.27 mp 163-164C); IR max 1724, 1626, 1537, 1344 cm
-1
;
 
1
H NMR (CDCl3)  7.67 (1 H, t, J = 8.2 Hz, 6-H), 7.75 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 7.93 
(1 H, d, J = 0.8 Hz, 4-H), 8.03 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.51 (1 H, dd, J = 8.2, 1.6 Hz), 
8.57 (1 H, ddd, J = 8.2, 1.6, 0.8 Hz, 8-H); 
19
F NMR (CDCl3)  -63.54 (s, CF3). Further elution 
yielded 12g (40 mg, 6%) as yellow crystals, with data as below. 
6.1.3. 5-Nitro-3-phenylisocoumarin (12b) and 3-methyl-5-nitroisocoumarin (12g). 
Method A. 
Compound 10
34
 was treated with 11b, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12a 
(Method B) (chromatographic eluent: hexane / EtOAc 10:1) to give 12b (4%) as yellow cryst-
als: mp 142-143C (lit.26 mp 142-143C); IR max 1739, 1525, 1341 cm
-1
; 
1
H NMR (CDCl3)  
7.50-7.53 (3 H, m, Ph 3,4,5-H3), 7.62 (1 H, t, J = 7.8 Hz, 7-H), 7.89 (1 H, d, J = 0.8 Hz, 4-H), 
7.93-7.97 (2 H, m, Ph 2,6-H2), 8.51 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.65 (1 H, dt, J = 8.2, 1.2, 
0.8 Hz, 8-H); MS (EI) m/z 267.0532 (M) (C15H9NO4 requires 267.0532). Further elution 
yielded 12g (170 mg, 8%) as yellow crystals, with data as below. 
6.1.4. 5-Nitro-3-phenylisocoumarin (12b). Method B. 
Compound 10
34
 (5.0 g, 20 mmol) and Cu powder (150 mg, 2.4 mmol) were added to 17b 
(22.9 g, 102 mmol) and KOBu
t
 (4.6 g, 41 mmol) in Bu
t
OH (100 mL). The mixture was boiled 
under reflux for 16 h, then poured into water and acidified with aq. HCl (2 M). This 
suspension was extracted (Et2O). Evaporation and chromatography (hexane / EtOAc 10:1) 
gave 12b (4.2 g, 78%) as yellow crystals, with data as above. 
6.1.5. 3-(4-Methylphenyl)-5-nitroisocoumarin (12c). 
Compound 10
34
 (22.7 g, 100 mmol) was treated with 11c, Cu and KOBu
t
 in Bu
t
OH, as for the 
synthesis of 12a (Method B) (chromatographic eluent: hexane / EtOAc 10:1) to give 12c 
(21%) as pale yellow crystals: mp 180-181°C (lit.
27
 mp 181-182C); 1H NMR (CDCl3)  2.42 
(3 H, s, Me), 7.29 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 7.57 (1 H, t, J = 8.2 Hz, 7-H), 7.82 (1 H, s, 
4-H), 7.83 (2 H, d, J = 8.4 Hz, Ph 2,6-H2), 8.48 (1 H, brd, J = 8.2 Hz, 6-H), 8.61 (1 H, brd, J = 
8.5 Hz, 8-H). Further elution yielded 12g (3%), with data as below. 
6.1.6. 3-(4-Methoxyphenyl)-5-nitroisocoumarin (12d). Method A. 
Compound 10
34
 was treated with 11d
40
, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12a 
(Method B) (chromatographic eluent: hexane / EtOAc 10:1) to give 12d (15%) as yellow 
crystals: mp 241-242C (lit.26 mp 241-242C); 1H NMR (CDCl3)  3.88 (3 H, s, Me), 6.99 (2 
H, d, J = 9.0 Hz, Ph 3,5-H2), 7.54 (1 H, t, J = 8.2 Hz, 7-H), 7.76 (1 H, s, 4-H), 7.88 (2 H, d, J 
= 9.0 Hz, Ph 2,6-H2), 8.46 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.59 (1 H, dd, J = 8.2, 1.2 Hz, 8-H);
 
13
C NMR (CDCl3) (Cq omitted)  55.56 (Me), 94.74 (4-C), 114.52 (Ph 3,5-C2), 126.56 (7-C), 
127.73 (Ph 2,6-C2), 131.71 (6-C), 135.92 (8-C); MS (EI) m/z 297.0639 (M) (C16H11NO5 
requires 297.0637), 266 (M - OMe). Further elution yielded 12g (6%) as yellow crystals, with 
data as below. 
6.1.7. 3-(4-Methoxyphenyl)-5-nitroisocoumarin (12d). Method B. 
Compound 10
34
 was treated with 17d,
43 
Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12b 
(Method B) (chromatographic eluent: hexane / EtOAc 4:1) to give 12d (61%) as yellow 
crystals, with data as above. 
6.1.8. 3-(4-Chlorophenyl)-5-nitroisocoumarin (12e). Method A. 
Compound 10
34
 was treated with 11e, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12a 
(Method B) (chromatographic eluent: hexane / EtOAc 8:1) to give 12e (33%) as pale yellow 
crystals: mp 204-205C; (lit.27 mp 204-205C); 1H NMR (CDCl3)  7.47 (2 H, d, J = 6.6 Hz, 
Ph 3,5-H2), 7.62 (1 H, t, J = 8.0 Hz, 7-H), 7.87 (2 H, d, J = 6.9 Hz, Ph 2,6-H2), 7.88 (1 H, brs, 
4-H), 8.50 (1 H, dd, J = 8.3, 1.9 Hz, 6-H), 8.63 (1 H, brd, J = 8.0 Hz, 8-H);
 13
C NMR  (Cq 
not observed) 96.62, 127.23, 127.50, 129.44, 131.74, 135.92; MS (EI) m/z 303.0111 (M) 
(C15H8
37
ClNO4 requires 303.0112), 301.0137 (M) (C15H8
35
ClNO4 requires 301.0142). Further 
elution yielded 12g (4%) as yellow crystals, with data as below. 
6.1.9. 5-Nitro-3-(thiophen-2-yl)isocoumarin (12f). 
Compound 10
34
 was treated with 11f,
44 
Cu and and KOBu
t
 in Bu
t
OH, as for the synthesis of 
12a (Method B) (chromatographic eluent: hexane / EtOAc 8:1) to give 12f (21%) as pale 
yellow crystals: mp 189-190C; IR max 1744, 1619, 1530, 1338 cm
-1
; 
1
H NMR (CDCl3)  
7.15 (1 H, dd, J = 5.1, 3.9 Hz, thiophene 4-H), 7.50 (1 H, dd, J = 5.1, 1.2 Hz, thiophene 5-H), 
7.55 (1 H, t, J = 8.2 Hz, 7-H), 7.71 (1 H, dd, J = 3.9, 1.2 Hz, thiophene 3-H), 7.71 (1 H, d, J = 
0.8 Hz, 4-H), 8.47 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.59 (1 H, ddd, J = 8.2, 1.2, 0.8 Hz, 8-H); 
MS (EI) m/z 273.0088 (M) (C13H7NO4S requires 273.0096). 
6.1.10. 3-Methyl-5-nitroisocoumarin (12g). 
Compound 10
34
 was treated with 11g, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12a 
(Method B) (chromatographic eluent: hexane / EtOAc 3:2) to give 12g (23%) as yellow 
crystals: mp 199-200C (lit.23 mp 199-200C); IR max 1746, 1648, 1520, 1331 cm
-1
; 
1
H NMR 
(CDCl3)  2.37 (3 H, s, Me), 7.13 (1 H, d, J = 0.8 Hz, 4-H), 7.55 (1 H, t, J = 8.2 Hz, 7-H), 
8.41 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.56 (1 H, ddd, J = 8.2, 1.2, 0.8 Hz, 8-H); 
13
C NMR  
20.46, 98.36, 121.92, 126.88, 131.36, 131.84, 135.74, 143.85, 158.63, 160.83; MS (EI) m/z 
205.0384 (M) (C10H7NO4 requires 205.0375); Anal. Calcd. for C10H7NO4: C, 58.54; H, 3.44; 
N, 6.83. Found: C, 58.3; H, 3.47; N, 6.78. 
6.1.11. 5-Nitro-3-pentylisocoumarin (12h). Method A. 
Compound 10
34
 was treated with 11h, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12a 
(Method B) (chromatographic eluent: hexane / EtOAc 10:1) to give 12h (4%) as a pale yellow 
oil: IR max (film) 1736, 1646, 1530, 1344 cm
-1
; 
1
H NMR (CDCl3)  0.90-0.94 (3 H, m, pentyl 
5-H3), 1.35-1.40 (4 H, m, pentyl 3,4-H4), 1.70-1.78 (2 H, m, pentyl 2-H2), 2.59 (2 H, t, J = 7.8 
Hz, pentyl 1-H2), 7.12 (1 H, d, J = 0.8 Hz, 4-H), 7.55 (1 H, t, J = 7.8 Hz, 7-H), 8.41 (1 H, dd, 
J = 7.8, 1.6 Hz, 6-H), 8.56 (1 H, ddd, J = 7.8, 1.6, 0.8 Hz, 8-H); 
13
C NMR  13.96, 22.37, 
26.61, 31.18, 34.20, 97.69, 122.08, 126.83, 131.34, 131.85, 135.71, 143.82, 160.99, 162.36; 
MS (EI) m/z 261.1002 (M) (C14H15NO4 requires 261.1001).  
6.1.12. 5-Nitro-3-pentylisocoumarin (12h). Method B. 
Compound 10
34
 was treated with 17h,
45
 Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12b 
(Method B) to give 12h (36%) as a pale yellow oil, with data as above. 
6.1.13. 5-Nitro-3-phenylmethylisocoumarin (12i). 
Compound 10
34
 was treated with 17i, as for the synthesis of 12b (Method B) 
(chromatographic eluent: hexane / EtOAc 9:1) to give 12i (32%) as yellow crystals: mp 137-
138C; IR max 1740, 1647, 1564, 1346 cm
-1
; 
1
H NMR (CDCl3)  3.88 (2 H, s CH2), 7.13 (1 
H, d, J = 0.5 Hz, 4-H), 7.247.36 (5 H, m, Ph-H5), 7.54 (1 H, t, J = 8.0 Hz, 7-H), 8.39 (1 H, 
dd, J = 8.0, 1.4 Hz, 6-H), 8.53 (1 H, ddd, J = 8.0, 1.4, 0.5 Hz, 8-H); MS (EI) m/z 281.0690 
(M) (C16H11NO4 requires 281.0688), 190 (M – Bn). 
6.1.14. 3-Ethyl-5-nitroisocoumarin (12j). 
Compound 10
34
 was treated with 17j, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12b 
(Method B) (chromatographic eluent: hexane / EtOAc 9:1) to give 12j (24%) as yellow 
crystals: mp 77-78C; IR max 1747, 1645, 1524, 1347 cm
-1
; 
1
H NMR (CDCl3)  1.17 (3 H, t, 
J = 7.6 Hz, Me), 2.55 (2 H, q, J = 7.6 Hz, CH2), 7.01 (1 H, d, J = 0.9 Hz, 4-H), 7.48 (1 H, t, J 
= 8.1 Hz, 7-H), 8.32 (1 H, dd, J = 8.1, 2.6 Hz, 6-H), 8.44 (1 H, ddd, J = 8.1, 2.6, 0.9 Hz, 8-H); 
13
C NMR  11.73, 27.99, 97.41, 122.65, 127.41, 131.89, 132.38, 136.22, 144.43, 161.43, 
163.92; MS (EI) m/z 219.0533 (M) (C11H9NO4 requires 219.0532). 
6.1.15. 3-(2-Methylpropyl)-5-nitroisocoumarin (12k). 
Compound 10
34
 treated with 17k, Cu and KOBu
t
 in Bu
t
OH, as for the synthesis of 12b 
(Method B) (chromatographic eluent: hexane / EtOAc 9:1) to give 12k (26%) as yellow 
crystals: mp 71-72C; IR max 1737, 1645, 1531, 1346 cm
-1
; 
1
H NMR  (CDCl3) 0.99 (6 H, d, 
J = 6.6 Hz, 2  Me), 2.16 (1 H, m, CH2CH), 2.45 (2 H, d, J = 7.4 Hz, CH2), 7.09 (1 H, s, 4-H), 
7.55 (1 H, t, J = 8.2 Hz, 7-H), 8.40 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.54 (1 H, dd, J = 8.2, 1.2 
Hz, 8-H); MS (EI) m/z 247.0848 (M) (C13H13NO4 requires 247.0845). 
6.1.16. 1,5-Diphenyl-2,4-pentanedione (17i) and ethyl 2,4-diphenyl-3-oxobutanoate (20). 
1-Phenylpropan-2-one 18 (26.8 g, 0.20 mol) in dry Et2O (50 mL) was added during 10 min to 
NaNH2 (50% in toluene, 31.2 ml, 0.40 mol) and dry Et2O (100 mL) and the mixture was 
stirred for 30 min. Ethyl phenylacetate 19 (65.6 g, 0.40 mol) in dry Et2O (50 mL) was added 
dropwise. The mixture was boiled under reflux for 2 h, poured into H2O (300 mL) and 
neutralised with aq HCl (2 M). The solution was extracted with Et2O. The solvent was 
evaporated. The residue was dissolved in an equal volume of MeOH. To this methanolic 
solution was added a hot solution of Cu(OAc)2 (40.0 g) in H2O (350 mL) and the mixture was 
allowed to stand until it cooled to 20C. The precipitated copper salt was filtered, washed 
with cold petroleum ether and shaken with a mixture of aq. H2SO4 (10%, 300 mL) and Et2O 
(100 mL) until the Et2O layer was colourless. Evaporation and recrystallisation (hexane / 
EtOAc) yielded 17i (26%) as orange crystals: mp 68-69C (lit.46 mp 65.5-66.5C); 1H NMR 
(CDCl3)  3.56 (4 H, s, 1,5-H4), 5.43 (1 H, s, 3-H), 7.18-7.32 (10 H, m, 2  Ph-H5), 15.27 (1 
H, br s, OH); MS (EI) m/z 252.1144 (M) (C17H16O2 requires 252.1150), 161 (M – CH2Ph), 
133 (M – COCH2Ph). Isolated from the methanolic mother liquor was 20 (41%) as colourless 
crystals: mp 76-78C (lit.47 mp 75C); IR max 1734, 1715 cm
-1
; 
1
H NMR (CDCl3)  1.22 (3 
H, t, J = 7.1 Hz, Me), 3.74 (2 H, s, 4-H2), 4.17 (2 H, q, J = 7.1 Hz, CH2Me), 4.81 (1 H, s, 2-
H), 7.05-7.39 (10 H, m, 2  Ph-H5); MS (EI) m/z 282.1255 (M) (C18H18O3 requires 282.1256). 
6.1.17. 5-Nitro-3-(4-trifluoromethylphenyl)isoquinolin-1-one (21a). 
Compound 12a (560 mg, 1.7 mmol) in MeO(CH2)2OH (50 mL) was saturated with NH3 and 
boiled under reflux for 4 h. The solvent and excess reagent were evaporated until 10 mL 
remained. The concentrate was stored at 4C for 16 h. The crystals were collected by 
filtration, washed (H2O, then EtOH) and recrystallised (MeOH) to give 21a (150 mg, 27%) as 
yellow crystals: mp 230-231C; 1H NMR ((CD3)2SO)  7.28 (1 H, s, 4-H), 7.68 (1 H, t, J = 
7.8 Hz, 7-H), 7.88 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 7.97 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.47 
(1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.58 (1 H, d, J = 7.8, 1.2 Hz, 8-H), 12.21 (1 H, brs, NH); 
19
F 
NMR ((CD3)2SO)  -61.84 (s, CF3); MS (EI) m/z 334.0560 (M) (C16H9F3N2O3 requires 
334.0565). 
6.1.18. 5-Nitro-3-phenylisoquinolin-1-one (21b). 
Compound 12b was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to 
give 21b (73%) as bright yellow crystals: mp 127-128C; IR max 3482, 1665, 1536, 1348 cm
-
1
; 
1
H NMR ((CD3)2SO)  7.25 (1 H, s, 4-H), 7.53-7.55 (3 H, m, Ph 3,4,5-H3), 7.66 (1 H, t, J = 
7.8 Hz, 7-H), 7.78-7.80 (2 H, m, Ph 2,6-H2), 8.49 (1 H, d, J = 7.8 Hz, 6-H), 8.60 (1 H, d, J = 
7.8 Hz, 8-H), 12.11 (1 H, br s, NH); MS (EI) m/z 266.0694 (M) (C15H10N2O3 
requires 266.0691).  
6.1.19. 3-(4-Methylphenyl)-5-nitroisoquinolin-1-one (21c). 
Compound 12c was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to give 
21c (86%) as bright yellow crystals: mp 175-176C; 1H NMR ((CD3)2SO)  2.37 (3 H, s, Me), 
7.20 (1 H, d, J = 0.8 Hz, 4-H), 7.32 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 7.62 (1 H, t, J = 8.2 Hz, 7-
H), 7.66 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.45 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.56 (1 H, ddd, J 
= 8.2, 1.2, 0.8 Hz, 8-H), 12.03 (1 H, brs, NH); MS (EI) m/z 280.0856 (M) (C16H12N2O3 
requires 280.0848); Anal. Calcd. for C16H12N2O3: C, 68.56; H, 4.32; N, 9.99. Found: C, 68.2; 
H, 4.28; N, 10.0. 
6.1.20. 3-(4-Methoxyphenyl)-5-nitroisoquinolin-1-one (21d). 
Compound 12d was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to 
give 21d (65%) as bright yellow crystals: mp 236-237C; IR max 3468, 1677, 1515, 1323 
cm
-1
; 
1
H NMR ((CD3)2SO)  3.82 (3 H, s, Me), 7.07 (2 H, d, J = 9.0 Hz, Ph 3,5-H2), 7.18 (1 
H, d, J = 0.8 Hz, 4-H), 7.60 (1 H, t, J = 8.2 Hz, 7-H), 7.73 (2 H, d, J = 9.0 Hz, Ph 2,6-H2), 
8.45 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.55 (1 H, ddd, J = 8.2, 1.2, 0.8 Hz, 8-H), 12.00 (1 H, br 
s, NH); MS (EI) m/z 296.0802 (M) (C16H12N2O4 requires 296.0797); Anal. Calcd. for 
C16H12N2O40.5H2O: C, 62.95; H, 4.26; N, 9.18. Found: C, 63.2; H, 4.12; N, 9.49. 
6.1.21. 3-(4-Chlorophenyl)-5-nitroisoquinolin-1-one (21e). 
Compound 12e was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to give 
21e (64%) as bright yellow crystals: mp 231-233C (decomp.); 1H NMR ((CD3)2SO)  7.22 
(1 H, d, J = 0.8 Hz, 4-H), 7.59 (2 H, d, J = 8.6 Hz, Me 3,5-H2), 7.65 (1 H, t, J = 8.2 Hz, 7-H), 
7.79 (2 H, d, J = 8.6 Hz, Ph 2,6-H2), 8.47 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.58 (1 H, ddd, J = 
8.2, 1.2, 0.8 Hz, 8-H), 12.13 (1 H, br s, NH); (FAB) m/z 303.0360 (M + H) (C15H10
37
ClN2O3 
requires 303.0350), 301.0377 (M + H) (C15H10
35
ClN2O3 requires 301.0380); Anal. Calcd. for 
C15H9ClN2O30.25H2O: C, 59.02; H, 3.11; N, 9.18. Found: C, 58.8; H, 3.11; N, 9.11. 
6.1.22. 5-Nitro-3-(thiophen-2-yl)isoquinolin-1-one (21f). 
Compound 12f was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to give 
21f (63%) as orange crystals: mp 225C (decomp.); IR max 3458, 1670, 1616, 1514, 1319 cm
-
1
; 
1
H NMR ((CD3)2SO)  7.21 (1 H, dd, J = 5.1, 3.9 Hz, thiophene 4-H), 7.33 (1 H, d, J = 0.8 
Hz, 4-H), 7.60 (1 H, t, J = 8.2 Hz, 7-H), 7.77 (1 H, dd, J = 5.1, 1.2 Hz, thiophene 5-H), 7.93 
(1 H, dd, J = 3.9, 1.2 Hz, thiophene 3-H), 8.47 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.54 (1 H, ddd, 
J = 8.2, 1.2, 0.8 Hz, 8-H), 12.13 (1 H, br s, NH); 
13
C NMR  (some Cq omitted) 95.84, 
125.24, 126.48, 127.88, 128.63, 129.12, 130.12, 130.88, 133.29; MS (EI) m/z 272.0257 (M) 
(C13H8N2O3S requires 272.0256); Anal. Calcd. for C13H8N2O3S0.25H2O: C, 56.42; H, 3.07; 
N, 10.13. Found: C, 56.7; H, 3.15; N, 10.0. 
6.1.23. 3-Methyl-5-nitroisoquinolin-1-one (21g). 
Compound 12g was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to 
give 21g (68%) as bright yellow crystals: mp 231-232C (lit.23 mp 231-232C); IR max 3435, 
1668, 1523, 1346 cm
-1
; 
1
H NMR ((CD3)2SO)  2.29 (3 H, s, Me), 6.78 (1 H, brs, 4-H), 7.55 (1 
H, t, J = 7.8 Hz, 7-H), 8.38 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.49 (1 H, ddd, J = 7.8, 1.2 Hz, 8-
H), 11.79 (1 H, brs, NH); MS (FAB) m/z 205.0617 (M + H) (C10H9N2O3 requires 205.0613), 
189 (M – Me); Anal. Calcd. for C10H8N2O3: C, 58.82; H, 3.95; N, 13.72. Found: C, 58.4; H, 
3.99; N, 13.5. 
6.1.24. 5-Nitro-3-pentylisoquinolin-1-one (21h). 
Compound 12h was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to 
give 21h (29%) as bright yellow crystals: mp 158-159C; IR max 3467, 1666, 1524, 1375 cm
-
1
; 
1
H NMR ((CD3)2SO)  0.86-0.89 (3 H, m, pentyl 5-H3), 1.28-1.34 (4 H, m, pentyl 3,4-H4), 
1.60-1.67 (2 H, m, pentyl 2-H2), 2.55 (2 H, t, J = 7.6 Hz, pentyl 1-H2), 6.79 (1 H, s, 4-H), 7.56 
(1 H, t, J = 7.8 Hz, 7-H), 8.39 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.50 (1 H, dd, J = 7.8, 1.2 Hz, 
8-H), 11.77 (1 H, brs, NH); MS (EI) m/z 260.1162 (M) (C14H16N2O3 requires 260.1161). 
6.1.25. 5-Nitro-3-phenylmethylisoquinolin-1-one (21i). 
Compound 12i was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to give 
21i (83%) as bright yellow crystals: mp 203-204C (decomp.); IR max 3186, 1645, 1524, 
1323 cm
-1
; 
1
H NMR ((CD3)2SO)  3.92 (2 H, s CH2), 6.80 (1 H, s, 4-H), 7.24-7.34 (5 H, m, 
Ph-H5), 7.57 (1 H, t, J = 7.8 Hz, 7-H), 8.39 (1 H, d, J = 7.8 Hz, 6-H), 8.49 (1 H, d, J = 7.8 Hz, 
8-H), 11.93 (1 H, br s, NH); MS (EI) m/z 280.0848 (M) (C16H12N2O3 requires 280.0848). 
6.1.26. 3-Ethyl-5-nitroisoquinolin-1-one (21j). 
Compound 12j was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to give 
21j (38%) as bright yellow crystals: mp 196-197C; IR max 3432, 1666, 1524, 1372 cm
-1
; 
1
H 
NMR ((CD3)2SO)  1.22 (3 H, t, J = 7.5 Hz, Me), 2.59 (2 H, q, J = 7.5 Hz, CH2), 6.80 (1 H, s, 
4-H), 7.56 (1 H, t, J = 8.1 Hz, 7-H), 8.40 (1 H, dd, J = 8.1, 1.5 Hz, 6-H), 8.51 (1 H, dd, J = 
8.1, 1.5 Hz, 8-H), 11.79 (1 H, brs, NH); MS (FAB) m/z 219.0779 (M + H) (C11H11N2O3 
requires 219.0770). 
6.1.27. 5-Nitro-3-(2-methylpropyl)isoquinolin-1-one (21k). 
Compound 12k was treated with NH3 in 2-methoxyethanol, as for the synthesis of 21a, to 
give 21k (89%) as bright yellow crystals: mp 184-185C; IR max 3436, 1655, 1523, 1376 cm
-
1
; 
1
H NMR ((CD3)2SO)  0.91 (6 H, d, J = 6.6 Hz, 2  Me), 1.97-2.04 (1 H, m, CH2CH), 2.43 
(2 H, d, J = 7.0 Hz, CH2), 6.77 (1 H, s, 4-H), 7.56 (1 H, t, J = 7.8 Hz, 7-H), 8.40 (1 H, dd, J = 
7.8, 1.2 Hz, 6-H), 8.50 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 11.76 (1 H, brs, NH); MS (EI) m/z 
246.1003 (M) (C13H14N2O3 requires 246.1004). 
6.1.28. 5-Amino-3-(4-trifluoromethylphenyl)isoquinolin-1-one (22a). Method A. 
Compound 21a (1.0 g, 3.0 mmol) was heated at 70C with SnCl2 (1.8 g, 9.5 mmol) in EtOH 
(50 mL) for 4 h, then poured into ice-H2O (200 mL). The suspension was made alkaline with 
aq. NaOH and filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation 
(hexane / EtOAc) gave 22a (360 mg, 40%) as yellow crystals: mp 214-215C; IR max 3419, 
3218, 1651 cm
-1
; 
1
H NMR ((CD3)2SO)  5.86 (2 H, br s, NH2), 6.88 (1 H, dd, J = 7.8, 1.2 Hz, 
6-H), 7.18 (1 H, t, J = 7.8 Hz, 7-H), 7.22 (1 H, s, 4-H), 7.40 (1 H, d, J = 7.8, 1.2 Hz, 8-H), 
7.82 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 8.02 (2 H, d, J = 8.2 Hz, 2,6-H2), 11.45 (1 H, brs, NH); 
19
F NMR ((CD3)2SO) F -61.60 (s, CF3); MS (FAB) m/z 305.0898 (M + H) (C16H12F3N2O 
requires 305.0902). A sample was converted into 22a.HCl salt: pale buff solid; mp >350C; 
1
H NMR ((CD3)2SO)  7.14 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.18 (1 H, s, 4-H), 7.31 (1 H, t, J 
= 7.8 Hz, 7-H), 7.63 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 7.85 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 8.01 
(2 H, d, J = 8.2 Hz, 2,6-H2), 11.60 (1 H, brs, NH); 
19
F NMR ((CD3)2SO)  -59.50 (s, CF3). A 
small sample of 22a was also converted into 22a.HBr salt: buff solid; mp >360C; IR νmax 
3414, 3165, 1647, 1327, 1170, 1116; 
1
H NMR ((CD3)2SO)  7.17 (2 H, m, 4,6-H2), 7.32 (1 H, 
t, J = 7.5 Hz, 7-H), 7.67 (1 H, d, J = 7.5 Hz, 8-H), 7.88 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 8.04 
(2 H, d, J = 8.0 Hz, Ph 2,6-H2), 11.63 (1 H, br, NH); 
13
C
 
NMR ((CD3)2SO) (HSQC / HMBC) 
 99.53 (4-C), 117.08 (8-C), 118.87 (6-C), 123.51 (8a-C), 124.11 (q, J = 270.6 Hz, CF3), 
125.64 (q, J = 3.5 Hz, Ph 3,5-C2), 126.28 (4a-C), 127.41 (7-C + Ph 2,6-C2), 129.20 (q, J = 
31.8 Hz, Ph 4-C), 136.82 (Ph 1-C), 137.83 (3-C), 139.92 (5-C), 162.46 (1-C); 
19
F NMR 
((CD3)2SO) d -61.02 (s, CF3); MS m/z (ES) 303.0756 (M - H) (C16H10F3N2O requires 
303.0745). 
6.1.29. 5-Amino-3-(4-trifluoromethylphenyl)isoquinolin-1-one hydrochloride (22a). 
Method B. 
Compound 21a (140 mg, 0.42 mmol) and Pd/C (10%, 70 mg) in EtOH (15 mL) and aq. HCl 
(34%, 0.4 mL) were stirred vigorously under H2 for 2 h. The suspension was filtered through 
Celite. The Celite pad and residue were suspended in water (100 mL) and heated. The hot 
suspension was filtered through a second Celite pad. Evaporation of the solvent and drying 
gave 21a (60 mg, 42%), with data as above. 
6.1.30. 5-Amino-3-phenylisoquinolin-1-one (22b). 
Compound 21b was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22b (57%) as yellow crystals: mp 215-217C; IR max 3569, 3329, 3230, 1655 cm
-1
; 
1
H 
NMR (CDCl3)  4.00 (2 H, br s, NH2), 6.64 (1 H, s, 4-H), 6.93 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 
7.22 (1 H, t, J = 7.8 Hz, 7-H), 7.36-7.45 (3 H, m, Ph 3,4,5-H3), 7.64-7.66 (2 H, m, Ph 2,6-H2), 
7.80 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 10.08 (1 H, br s, NH); MS m/z (FAB) 237.1019 (M + H) 
(C15H13N2O requires 237.1028). Compound 22b (50 mg, 0.2 mmol) was stirred with aq. HCl 
(2 M, 20 mL) for 30 min. Evaporation and recrystallisation (MeOH) yielded 22b.HCl salt (53 
mg, 91%) as a pale buff solid: mp 192-193C; 1H NMR (D2O)  6.98 (1 H, s, 4-H), 7.52-7.59 
(3 H, m, Ph 3,4,5-H3), 7.59 (1 H, t, J = 8.1 Hz, 7-H), 7.68-7.75 (2 H, m, Ph 2,6-H2), 7.84 (1 H, 
d, J = 8.1 Hz, 6-H), 8.31 (1 H, d, J = 8.1 Hz, 8-H). A small sample of 22b was also converted 
into 22b.HBr salt: pale buff solid; mp 274-275C; IR νmax 3425, 2923, 1629; 
1
H NMR 
(CD3OD) 7.10 (1 H, s, 4-H), 7.28 (1 H, d, J = 7.7 Hz, 6-H), 7.38 (1 H, t, J = 7.8 Hz, 7-H), 
7.55 (3 H, m, Ph 3,4,5-H3), 7.80 (1 H, d, J = 7.6 Hz, 8-H), 7.87 (2 H, m, Ph 2,6-H2), 11.55 (1 
H, s, N-H); 
13
C
 
NMR (CD3OD) (HSQC / HMBC)98.36 (4-C), 127.45 (4a-C), 127.67 (7-C), 
128.13 (Ph 2,6-C2), 128.96 (8-C), 129.46 (6-C), 130.32 (Ph 3,4,5-C3), 131.34 (Ph 4-C), 
134.00 (8a-C), 135.28 (Ph 1-C), 144.34 (5-C), 164.63 (1-C). 
6.1.31. 5-Amino-3-(4-methylphenyl)isoquinolin-1-one (22c). Method A. 
Compound 21c was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22c (92%) as pale yellow crystals: mp 213-214C; IR max 3476, 3253, 1669 cm
-1
; 
1
H 
NMR (CDCl3)  2.41 (3 H, s, Me), 4.06 (2 H, br, NH2), 6.68 (1 H, s, 4-H), 6.99 (1 H, d, J = 
7.8 Hz, 6-H), 7.28 (1 H, t, J = 7.8 Hz, 7-H), 7.29 (2 H, d, J = 7.8 Hz, Ph 3,5-H2), 7.59 (2 H, d, 
J = 7.8 Hz, Ph 2,6-H2), 7.86 (1 H, d, J = 7.8 Hz, 8-H), 9.92 (1 H, br, NH); MS m/z (FAB) 
251.1181 (M + H) (C16H15N2O requires 251.1184). A sample was converted into 22c.HCl 
salt: pale buff solid; mp >350C; 1H NMR ((CD3)2SO)  2.23 (3 H, s, Me), 6.48 (1 H, s, 4-H), 
7.31 (2 H, d, J = 7.8 Hz, Ph 3,5-H2), 7.36 (1 H, t, J = 7.8 Hz, 7-H), 7.61 (1 H, d, J = 7.8 Hz, 
6-H), 7.75 (1 H, d, J = 7.8 Hz, 8-H), 7.96 (2 H, d, J = 7.8 Hz, Ph 2,6-H2), 11.47 (1 H, br, NH). 
6.1.32. 5-Amino-3-(4-methylphenyl)isoquinolin-1-one hydrochloride (22c). Method B. 
Compound 21c was treated with H2 and Pd/C in EtOH and aq. HCl, as for the synthesis of 
22a (Method B), to give 22c (79%) as a pale buff solid, with data as above. 
6.1.33. 5-Amino-3-(4-methoxyphenyl)isoquinolin-1-one (22d). 
Compound 21d (80 mg, 0.3 mmol) was treated with SnCl2 in EtOH, as for the synthesis of 
22a (Method A), to give 22d (83%) as yellow crystals: mp 189-190C; IR max 3438, 3233, 
1660 cm
-1
; 
1
H NMR (CDCl3)  3.86 (3 H, s, Me), 4.11 (2 H, br, NH2), 6.64 (1 H, s, 4-H), 6.97 
(1 H, dd, J = 7.8, 1.2 Hz, 6-H), 6.99 (2 H, d, J = 8.8 Hz, Ph 3,5-H2), 7.25 (1 H, t, J = 7.8 Hz, 
7-H), 7.66 (2 H, d, J = 8.8 Hz, Ph 2,6-H2), 7.85 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 10.45 (1 H, 
brs, NH); MS (FAB) m/z 267.1132 (M + H) (C16H15N2O2 requires 267.1134). A sample was 
converted into 22d.HCl salt: buff solid; mp >350C; 1H NMR (D2O)  3.86 (3 H, s, OMe), 
6.84 (2 H, d, J = 8.1 Hz, Ph 3,5-H2), 6.92 (1 H, s, 4-H), 7.11 (1 H, t, J = 8.1 Hz, 7-H), 7.55 (1 
H, d, J = 8.1 Hz, 6-H), 7.70 (1 H, d, J = 8.1 Hz, 8-H), 7.94 (2 H, J = 8.1 Hz, Ph 2,6-H2). 
6.1.34. 5-Amino-3-(4-chlorophenyl)isoquinolin-1-one (22e). 
Compound 21e was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22e (41%) as yellow crystals: mp 231-232C; IR max 3548, 3338, 3236, 1654 cm
-1
; 
1
H 
NMR ((CD3)2SO)  5.81 (2 H, br, NH2), 6.86 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.11 (1 H, s, 4-
H), 7.15 (1 H, t, J = 7.8 Hz, 7-H), 7.38 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 7.53 (2 H, d, J = 6.6 
Hz, Ph 3,5-H2), 7.83 (2 H, d, J = 6.6 Hz, Ph 2,6-H2), 11.34 (1 H, brs, NH); MS (FAB) m/z 
273.0618 (M + H) (C15H12
37
ClN2O requires 273.0609), 271.0629 (M + H) (C15H12
35
ClN2O 
requires 271.0638). A sample was converted into 22e.HCl salt: buff solid; mp >350C; 1H 
NMR ((CD3)2SO)  7.08 (1 H, s, 4-H), 7.14 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.28 (1 H, t, J = 
7.8 Hz, 7-H), 7.56 (2 H, d, J = 9.0 Hz, Ph 3,5-H2), 7.64 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 7.83 (2 
H, d, J = 9.0 Hz, Ph 2,6-H2), 11.50 (1 H, brs, NH); 
13
C
 
NMR ((CD3)2SO) (HSQC / HMBC) 
98.36 (4-C), 119.82 (8-C), 120.94 (6-H), 125.98 (8a-C), 126.92 (7-C), 127.68 (4a-C), 
128.36 (Ph 2,6-C2), 128.75 (Ph 3,5-C2), 132.77 (Ph 1-C), 133.93 (Ph 4-C), 136.71 (5-C), 
138.30 (3-C), 160.61 (1-C). 
6.1.35. 5-Amino-3-(thiophen-2-yl)isoquinolin-1-one (22f). 
Compound 21f was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22b (66%) as yellow crystals: mp 229-230C; IR max 3470, 3365, 1659 cm
-1
; 
1
H NMR 
(CDCl3)  4.03 (2 H, br s, NH2), 6.70 (1 H, s, 4-H), 6.99 (1 H, dd, J = 7.8, 1.1 Hz, 6-H), 7.14 
(1 H, dd, J = 4.9, 3.8 Hz, thiophene 4-H), 7.28 (1 H, t, J = 7.8 Hz, 7-H), 7.37 (1 H, dd, J = 4.9, 
1.1 Hz, thiophene 5-H), 7.49 (1 H, dd, J = 3.8, 1.1 Hz, thiophene 3-H), 7.86 (1 H, dd, J = 7.8, 
1.1 Hz, 8-H), 9.50 (1 H, br s, NH); MS (EI) m/z 242.0517 (M) (C13H10N2OS requires 
242.0514). A sample was converted into 22f.HCl salt: buff solid: mp >350C; 1H NMR (D2O) 
 6.87 (1 H, s, 4-H), 7.07 (1 H, dd, J = 4.9, 3.8 Hz, thiophene 4-H), 7.26 (1 H, d, J = 4.9 Hz, 
thiophene 5-H), 7.53 (1 H, d, J = 3.8 Hz, thiophene 3-H), 7.58 (1 H, t, J = 7.8 Hz, 7-H), 7.77 
(1 H, d, J = 7.8 Hz, 6-H), 8.22 (1 H, d, J = 7.8 Hz, 8-H). 
6.1.36. 5-Amino-3-methylisoquinolin-1-one (22g). 
Compound 21g was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22g (59%) as pale yellow crystals: mp 183-184C (lit.23 mp 183-184C); IR max 3467, 
3375, 3298, 1655 cm
-1
; 
1
H NMR ((CD3)2SO)  2.18 (3 H, s, Me), 5.47 (2 H, br, NH2), 6.44 (1 
H, s, 4-H), 6.80 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.05 (1 H, t, J = 7.8 Hz, 7-H), 7.32 (1 H, dd, J 
= 7.8, 1.2 Hz, 8-H), 11.06 (1 H, brs, NH); MS m/z (FAB) 175.0874 (M + H) (C10H11N2O 
requires 175.0871), 159 (M – Me). A sample was converted into 22g.HCl salt: pale buff solid: 
mp >350C; IR max 3414, 2851, 1685 cm
-1
; 
1
H NMR ((CD3)2SO) (COSY / NOESY)  2.23 
(3 H, s, Me), 6.48 (1 H, s, 4-H), 7.37 (1 H, t, J = 7.8 Hz, 7-H), 7.69 (1 H, d, J = 7.8 Hz, 6-H), 
7.99 (1 H, d, J = 7.8 Hz, 8-H), 11.50 (1 H, brs, NH); 
13
C NMR ((CD3)2SO) (HMQC, HMBC) 
19.21 (Me), 97.20 (4-C), 125.25 (8-C), 125.51 (6-C), 125.7 (8a-C), 126.2 (7-C), 130.3 (4a-C), 
138.79 (3-C), 140.0 (5-C), 161.99 (1-C); Anal. Calcd. for C10H11ClN2O: C, 57.02; H, 5.26; N, 
13.30. Found: C, 56.82; H, 5.01; N, 13.45. 
6.1.37. 5-Amino-3-pentylisoquinolin-1-one (22h). 
Compound 21h was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22h (67%) as yellow crystals: mp 75-76C; IR max 3448, 3395, 3166, 1651 cm
-1
; 
1
H 
NMR  0.76-0.88 (3 H, m, pentyl 5-H3), 1.21-1.34 (4 H, m, pentyl 3,4-H4), 1.66-1.78 (2 H, m, 
pentyl 2-H2), 2.57 (2 H, t, J = 7.6 Hz, pentyl 1-H2), 3.94 (2 H, br s, NH2), 6.21 (1 H, s, 4-H), 
6.92 (1 H, dd, J = 7.7, 1.2 Hz, 6-H), 7.20 (1 H, t, J = 7.7 Hz, 7-H), 7.84 (1 H, dd, J = 7.7, 1.2 
Hz, 8-H), 11.75 (1 H, brs, NH); MS (EI) m/z 230.1418 (M) (C14H18N2O requires 230.1419). A 
sample was converted into 22h.HCl salt: buff solid; mp 129-130C; 1H NMR (D2O)  0.74-
0.82 (3 H, m, pentyl 5-H3), 1.19-1.29 (4 H, m, pentyl 3,4-H4), 1.55-1.66 (2 H, m, pentyl 2-
H2), 2.55 (2 H, t, J = 7.6 Hz, pentyl 1-H2), 6.53 (1 H, s, 4-H), 7.49 (1 H, t, J = 7.8 Hz, 7-H), 
7.74 (1 H, d, J = 7.8 Hz, 6-H), 8.20 (1 H, d, J = 7.8 Hz, 8-H). 
6.1.38. 5-Amino-3-phenylmethylisoquinolin-1-one (22i). 
Compound 21i was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22i (64%) as yellow crystals: mp 85-86C; IR max 3469, 3394, 3162, 1661 cm
-1
; 
1
H 
NMR (CDCl3)  3.91 (2 H, s CH2), 4.00 (2 H, br s, NH2), 6.72 (1 H, d, J = 8.1 Hz, 6-H), 6.86 
(1 H, s, 4-H), 6.91 (1 H, t, J = 8.1 Hz, 7-H), 7.177.43 (5 H, m, Ph-H5), 7.83 (1 H, d, J = 8.1 
Hz, 8-H), 10.94 (1 H, br s, NH); MS (EI) m/z 250.1100 (M) (C16H14N2O requires 250.1106). 
A sample was converted into 22i.HCl salt: buff solid; mp >350C; 1H NMR (D2O)  3.94 (2 
H, s CH2), 6.49 (1 H, s, 4-H), 7.257.37 (5 H, m, Ph-H5), 7.51 (1 H, t, J = 7.8 Hz, 7-H), 7.73 
(1 H, d, J = 7.8 Hz, 6-H), 8.23 (1 H, d, J = 7.8 Hz, 8-H). 
6.1.39. 5-Amino-3-ethylisoquinolin-1-one (22j). 
Compound 21j was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22j (24%) as pale yellow crystals: mp 162-163C; IR max 3447, 3395, 3164, 1646 cm
-1
; 
1
H NMR ((CD3)2SO)  1.21 (3 H, t, J = 7.5 Hz, Me), 2.47 (2 H, q, J = 7.4 Hz, CH2), 5.51 (2 
H, br s, NH2), 6.44 (1 H, d, J = 0.8 Hz, 4-H), 6.80 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.05 (1 H, t, 
J = 7.8 Hz, 7-H), 7.33 (1 H, ddd, J = 7.8, 1.2, 0.8 Hz, 8-H), 11.04 (1 H, brs, NH); MS (FAB) 
m/z 189.1026 (M + H) (C11H13N2O requires 189.1028). Anal. Calcd. for (C11H12N2O.0.25 
H2O) C, 68.57; H, 6.49; N, 14.55; Found: C, 68.9; H, 6.45; N, 14.3. A sample was converted 
into 22j.HCl salt: buff solid; mp 133-134C; 1H NMR ((CD3)2SO)  1.22 (3 H, t, J = 7.4 Hz, 
Me), 2.53 (2 H, q, J = 7.4 Hz, CH2), 6.44 (1 H, s, 4-H), 7.34 (1 H, t, J = 7.8 Hz, 7-H), 7.47 (1 
H, dd, J = 7.8, 1.2 Hz, 6-H), 7.91 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 11.41 (1 H, brs, NH). 
6.1.40. 5-Amino-3-(2-methylpropyl)isoquinolin-1-one (22k). 
Compound 21k was treated with SnCl2 in EtOH, as for the synthesis of 22a (Method A), to 
give 22k (83%) as yellow crystals: mp 113-114C; IR max 3468, 3396, 3165, 1645 cm
-1
; 
1
H 
NMR (CDCl3)  0.82 (6 H, d, J = 6.4 Hz, 2  Me), 1.90-2.02 (1 H, m, CH2CH), 2.32 (2 H, d, 
J = 7.4 Hz, CH2), 3.99 (2 H, br, NH2), 6.14 (1 H, s, 4-H), 6.84 (1 H, dd, J = 7.9, 1.2 Hz, 6-H), 
7.10 (1 H, t, J = 7.9 Hz, 7-H), 7.71 (1 H, dd, J = 7.9, 1.2 Hz, 8-H), 11.52 (1 H, br s, NH); MS 
(EI) m/z 216.1263 (M) (C13H16N2O requires 216.1263). A sample was converted into 22k.HCl 
salt: buff crystals; mp 151-152C; 1H NMR (D2O)  0.88 (6 H, d, J = 6.6 Hz, 2  Me), 1.89-
1.93 (1 H, m, CH2CH), 2.47 (2 H, d, J = 7.4 Hz, CH2), 6.52 (1 H, s, 4-H), 7.50 (1 H, t, J = 7.9 
Hz, 7-H), 7.76 (1 H, d, J = 7.9 Hz, 6-H), 8.22 (1 H, d, J = 7.9 Hz, 8-H).  
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